C.Diff Vaccine Shows Promise in Phase II Trial

Results of a Phase II clinical trial ofPfizer’s preventive vaccine againstClostridium difficile (C. diff) showed the vaccine was safe and stimulated a C. diff targeted immune response.

FDA Approves Gammaplex 10% to Treat Adult PI and ITP Patients

The U.S. Food and Drug Administration has approved Bio Products Laboratory’s Gammaplex 10% (immune globulin intravenous [human] 10% liquid) for the treatment of primary immunodeficiency (PI) and chronic immune thrombocytopenic purpura in adults.